No advantage of Sodium Bicarbonate and Acetyl cysteine in Preventing Contrast Nephropathy
Steven D. Weisbord et al in NEJM published the results of Prevention of Serious Adverse Events Following Angiography (PRESERVE) trial which was done compare intravenous sodium bicarbonate with intravenous sodium chloride and oral acetylcysteine with oral placebo for the prevention of major adverse outcomes and acute kidney injury in a large population of high-risk patients undergoing coronary or noncoronary angiography.
Among patients at high risk for renal complications who were undergoing angiography, there was no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over placebo for the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of contrast-associated acute kidney injury.
Reference and Further Reading
- Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. The article was published on November 12, 2017, at NEJM.org.DOI:10.1056/NEJMoa1710933
No advantage of Sodium Bicarbonate and Acetyl cysteine in Preventing Contrast Nephropathy
Reviewed by Sumer Sethi
on
Monday, November 27, 2017
Rating:
Reviewed by Sumer Sethi
on
Monday, November 27, 2017
Rating:
Sumer Sethi
Unique blend of academic excellence and entrepreneurship, heading leading firms in India- Teleradiology Providers, pioneering company providing teleradiology services and DAMS (Delhi Academy of Medical Sciences) Premier test preparation institute in India for MD/MS/MCI preparation. He has also been an invited faculty member at various conferences, including Teleradiology in IRIA 2008 and 2011, Hospital Build Middle East, Congress of the Brain Tumor Radiology in Neuro-oncology Society. Dr. Sethi is Editor-in-Chief of Internet Journal of Radiology. He has a keen interest in Web 2.0 technologies and in maintaining his famous radiology blog, which has been featured in multiple international journals.
No comments:
Post a Comment